<?xml version='1.0' encoding='utf-8'?>
<document id="24867984"><sentence text="Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides." /><sentence text="Simeprevir (SMV), asunaprevir (ASV), daclatasvir (DCV), and sofosbuvir (SFV), which are newly developed direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) infection, are among the key components of anti-HCV regimens"><entity charOffset="0-10" id="DDI-PubMed.24867984.s2.e0" text="Simeprevir" /><entity charOffset="12-15" id="DDI-PubMed.24867984.s2.e1" text="SMV" /><entity charOffset="18-29" id="DDI-PubMed.24867984.s2.e2" text="asunaprevir" /><entity charOffset="31-34" id="DDI-PubMed.24867984.s2.e3" text="ASV" /><entity charOffset="37-48" id="DDI-PubMed.24867984.s2.e4" text="daclatasvir" /><entity charOffset="50-53" id="DDI-PubMed.24867984.s2.e5" text="DCV" /><entity charOffset="60-70" id="DDI-PubMed.24867984.s2.e6" text="sofosbuvir" /><entity charOffset="72-75" id="DDI-PubMed.24867984.s2.e7" text="SFV" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e0" e2="DDI-PubMed.24867984.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e0" e2="DDI-PubMed.24867984.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e0" e2="DDI-PubMed.24867984.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e0" e2="DDI-PubMed.24867984.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e0" e2="DDI-PubMed.24867984.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e0" e2="DDI-PubMed.24867984.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e0" e2="DDI-PubMed.24867984.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e0" e2="DDI-PubMed.24867984.s2.e7" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e1" e2="DDI-PubMed.24867984.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e1" e2="DDI-PubMed.24867984.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e1" e2="DDI-PubMed.24867984.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e1" e2="DDI-PubMed.24867984.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e1" e2="DDI-PubMed.24867984.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e1" e2="DDI-PubMed.24867984.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e1" e2="DDI-PubMed.24867984.s2.e7" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e2" e2="DDI-PubMed.24867984.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e2" e2="DDI-PubMed.24867984.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e2" e2="DDI-PubMed.24867984.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e2" e2="DDI-PubMed.24867984.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e2" e2="DDI-PubMed.24867984.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e2" e2="DDI-PubMed.24867984.s2.e7" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e3" e2="DDI-PubMed.24867984.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e3" e2="DDI-PubMed.24867984.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e3" e2="DDI-PubMed.24867984.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e3" e2="DDI-PubMed.24867984.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e3" e2="DDI-PubMed.24867984.s2.e7" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e4" e2="DDI-PubMed.24867984.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e4" e2="DDI-PubMed.24867984.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e4" e2="DDI-PubMed.24867984.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e4" e2="DDI-PubMed.24867984.s2.e7" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e5" e2="DDI-PubMed.24867984.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e5" e2="DDI-PubMed.24867984.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e5" e2="DDI-PubMed.24867984.s2.e7" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e6" e2="DDI-PubMed.24867984.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24867984.s2.e6" e2="DDI-PubMed.24867984.s2.e7" /></sentence><sentence text=" Preclinical studies have identified inhibitory properties for some of these DAAs against organic anion transporting polypeptide 1B (OATP1B) functions" /><sentence text=" However, their details remain mostly uncharacterized" /><sentence text=" Because OATP1B1 and OATP1B3 play determinant roles in the pharmacokinetics of various drugs via their uptake into human hepatocytes, it is plausible that the inhibition of these OATP1Bs by a DAA would create a potential risk of drug-drug interaction, which has been an emerging concern in anti-HCV therapy" /><sentence text=" Accordingly, in the present study, we intended to clarify the inhibitory characteristics of newly developed DAAs toward OATP1B1 and -1B3 functions" /><sentence text=" The results of our coincubation inhibition assays have shown that all tested DAAs could inhibit OATP1B1 functions and that SMV, ASV, and DCV (to a lesser extent), but not SFV, exhibited long-lasting preincubation inhibitory effects on OATP1B1 functions"><entity charOffset="124-126" id="DDI-PubMed.24867984.s7.e0" text="SMV" /><entity charOffset="129-131" id="DDI-PubMed.24867984.s7.e1" text="ASV" /><entity charOffset="138-140" id="DDI-PubMed.24867984.s7.e2" text="DCV" /><entity charOffset="172-174" id="DDI-PubMed.24867984.s7.e3" text="SFV" /><pair ddi="false" e1="DDI-PubMed.24867984.s7.e0" e2="DDI-PubMed.24867984.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24867984.s7.e0" e2="DDI-PubMed.24867984.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24867984.s7.e0" e2="DDI-PubMed.24867984.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24867984.s7.e0" e2="DDI-PubMed.24867984.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24867984.s7.e1" e2="DDI-PubMed.24867984.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24867984.s7.e1" e2="DDI-PubMed.24867984.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24867984.s7.e1" e2="DDI-PubMed.24867984.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24867984.s7.e2" e2="DDI-PubMed.24867984.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24867984.s7.e2" e2="DDI-PubMed.24867984.s7.e3" /></sentence><sentence text=" It was also found that the preincubation inhibitory effects of SMV and ASV could augment their coincubation inhibition potency"><entity charOffset="64-66" id="DDI-PubMed.24867984.s8.e0" text="SMV" /><entity charOffset="72-74" id="DDI-PubMed.24867984.s8.e1" text="ASV" /><pair ddi="false" e1="DDI-PubMed.24867984.s8.e0" e2="DDI-PubMed.24867984.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24867984.s8.e0" e2="DDI-PubMed.24867984.s8.e1" /></sentence><sentence text=" Furthermore, significant, but differential, inhibitory effects of the DAAs on the OATP1B3 function were identified" /><sentence text=" To summarize, our results clearly show that the newly developed DAAs are newly identified OATP1B1 and OATP1B3 inhibitors with distinctive interaction properties" /><sentence text=" It is believed that these inhibition profiles will provide essential information to all concerned parties with respect to the clinical significance of DAA-mediated inhibition of OATP1Bs in anti-HCV therapy" /><sentence text=" " /></document>